Item 2. Unregistered Sales of Equity Securities
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer purchases of equity securities for the three months ended June 30, 2026 were as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
($ in millions)
Period Total Number
of Shares
Purchased (1)
Average Price
Paid Per
Share Total Number of Shares
Purchased as Part of
Publicly Announced Plans or
Programs
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs (1)
April 1 - April 30
2,038,900 $116.77 2,038,900 $6,209
May 1 - May 31
2,105,318 $114.24 2,105,318 $5,968
June 1 - June 30
1,957,209 $118.81 1,957,209 $5,736
Total 6,101,427 $116.55 6,101,427
(1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in January 2025 to purchase up to $10 billion of Merck’s common stock for its treasury.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.